Open AccessFulminant myocarditis after the second dose of COVID‐19 mRNA vaccination
Author(s) -
Oka Akihiro,
Sudo Yuya,
Miyoshi Toru,
Ozaki Masatomo,
Kimura Yuta,
Takagi Wataru,
Ugawa Satoko,
Okada Tomoaki,
Nosaka Kazumasa,
Doi Masayuki
Publication year - 2022
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.5378
Subject(s) - medicine , myocarditis , cardiogenic shock , fulminant , vaccination , covid-19 , adverse effect , shock (circulatory) , cardiology , virology , disease , myocardial infarction , infectious disease (medical specialty)
Myocarditis is an adverse event associated with coronavirus disease 2019 (COVID‐19) mRNA vaccination. A 50‐year‐old man presented with dyspnea and resting chest pain after receiving the second dose of the COVID‐19 mRNA vaccine and developed cardiogenic shock. Fulminant myocarditis was diagnosed by endomyocardial biopsy and treated with intravenous corticosteroids.